版本:
中国

BRIEF-Blueprint Medicines announces proof-of-concept data from Phase 1 clinical trial of BLU-285

Nov 30 Blueprint Medicines Corp

* Blueprint Medicines announces proof-of-concept data from Phase 1 clinical trial of BLU-285 in patients with advanced gastrointestinal stromal tumors

* As of data cutoff date of November 1, 2016, BLU-285 was observed to be well-tolerated at all doses Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐